Enliven Therapeutics (ELVN) shares are in focus after the company reported encouraging initial Phase 1b data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients, with efficacy and ...

Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...

Everyday life is saturated with location-dependent devices. They are multiplying faster than ever and their requirements have ...

SELLAS Life Sciences Group recently reported that its Phase 3 REGAL trial of galinpepimut‑S (GPS) in Acute Myeloid Leukemia ...

For generations, biology textbooks treated life and death as a clean binary: an organism was either functioning or finished.

Credo’s AEC cable boom is beating revenue and lifting guidance; hyperscaler ramps add upside. Read here for an investment ...

Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...

Experts debate if 2026 will bring a deep crypto bear market or structural growth, as BTC’s classic cycle may no longer apply.

Modulation advances have fueled more efficient use of bandwidth, although conventional modulation formats still require allowance for upper and lower sidebands around the carrier frequency. Ultra ...

Analysts are intrested in these 5 stocks: ( ($AME) ), ( ($MNMD) ), ( ($ATAI) ), ( ($PRME) ) and ( ($KBH) ). Here is a breakdown of their recent ...

CoinEx's base case forecasts Bitcoin reaching $180,000 by 2026, but warns that the era of broad altcoin rallies is over. Liquidity will favor only proven "Blue-Chip Survivors" with real adoption.

Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.